What is the purpose of this trial?
This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to grow and spread.
Southwest Oncology Group (SWOG)
Start Date: 10/02/2018
End Date: 06/30/2020
Last Updated: 10/30/2018
Study HIC#: 2000023053